IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Company/Organization Date Area of
Collaboration
Terms of Agreement
BF Research Institute 2001 Dementia Basic research for development of
medicines for dementia.
NEDO Project 2001 Compound screening Co-development of a support system to
screen pharmaceutical compounds.
Sumitomo 2001 Automated
workstations
Array BioPharma 2001 Small molecule drug
discovery
The Institute of Physical
and Chemical Research
WHO 2001 Antimalarial drug
discovery
Research into a high-performance
automated chemistry workstation for
optimization of chemical reactions.
Takeda will pay fees to Array based on the
number of Array scientists working on the
research phase of the agreement. Array
will be entitled to receive milestone
payments and royalties based on products
resulting from the collaboration. Other
terms were not announced in 2004.
2001 Gene therapy Joint research into the physiological
function of p51 oncogene, an original form
of p53, and its application to medical
treatment.
Joint research into antimalarial drug
discovery.
Gedeon Richter 2001 Novel drug discovery Joint research into discovery of novel drug
candidate compounds.
Discovery Partners
International
Vical/Human Genome
Sciences
2001 Drug discovery
research
collaboration
2001 Drug design
technology
Discovery Partners International
announced the expansion of an existing
agreement with Takeda to include
significant drug discovery research
collaboration.
Licensing agreement between Vical and
Human Genome Sciences, which uses
Vical’s naked DNA technology and HGS’
proprietary genomics database. Vical will
receive exclusive rights to three genes
from HGS’ gene discovery program, in
return for the use of Vical’s technology to
deliver 3 different gene therapy products.
Celera Genomics 2000 Genomic database A five-year agreement that will provide
Takeda with subscriptions to Celera’s
genome databases and products, including
the Human Genome Database.
© 2009 IMS Health In cor po rated or its af fil i ates Page 105